AOD-9604 (2mg Vial)

01 · At a glance

Quickstart Highlights

AOD-9604 (human growth hormone fragment 177–191) is a short peptide investigated for its effects on fat metabolism. In preclinical and early clinical research, it has shown lipolytic and anti‑lipogenic activity without elevating IGF‑1 or impairing glucose tolerance. This page provides an educational dosing and reconstitution framework commonly used for daily subcutaneous administration. Typical educational starting dose: 200–300 mcg once daily; gradual titration to 400–500 mcg as tolerated Reconstitution: Add 3.0 mL bacteriostatic water to the 2 mg vial (≈0.667 mg/mL) Syringe math (100‑unit insulin syringe): 10 units ≈ 0.10 mL ≈ 66.7 mcg Storage: Keep lyophilized vials frozen (≈ −20 °C); refrigerate reconstituted solution (2–8 °C), protected from light Frequency: Once daily subcutaneous injection (e.g., morning); maintain consistent timing

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Approach (3 mL = 0.667 mg/mL)

Reference dose shown on this page: See guide.

Reconstitution Steps

1. Confirm the vial amount, unit, and diluent amount before entering values in the calculator.
2. Add diluent slowly down the inner wall of the vial when reconstitution is appropriate for the compound.
3. Swirl or roll gently until dissolved; avoid shaking unless the product instructions specifically say otherwise.
4. Label the vial with the date and concentration, then store according to the protocol and product instructions.

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Goal: Support fat‑metabolism‑focused body‑composition efforts
• Schedule: Subcutaneous injections, 1× daily , for 8–12 weeks (extend to 16 weeks if desired)
• Dose Range: 0.2–0.5 mg per day
• Reconstitution: 3.0 mL per 2 mg vial (≈0.667 mg/mL) keeps syringe units ≥10
• Storage: Lyophilized ≈ −20 °C; after mixing, refrigerate at 2–8 °C; avoid repeated freeze–thaw

Dosing Protocol

• Gradual titration helps assess individual tolerance while keeping measurements practical on an insulin syringe.
• Start: 200–300 mcg once daily Titrate: Increase by ~100 mcg every 2 weeks toward 400–500 mcg once daily Cycle length: 8–12 weeks (optional 4‑week extension at 500 mcg/day)
• Timing: Any consistent time of day (many choose mornings) Concentration tip: If volume feels large at 500 mcg (0.75 mL with 3 mL dilution), consider 2.0 mL reconstitution to reduce per‑injection volume to 0.50 mL

Storage Instructions

• Keep lyophilized vials frozen (≈ −20 °C); refrigerate reconstituted solution (2–8 °C), protected from light
• Storage: Lyophilized ≈ −20 °C; after mixing, refrigerate at 2–8 °C; avoid repeated freeze–thaw
• Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

• Context and considerations drawn from published research.
• Evidence base: Human obesity trials primarily used oral dosing (e.g., 1 mg/day) with mixed efficacy findings.
• High‑quality studies of daily subcutaneous dosing for body‑weight outcomes remain limited.
• Metabolic profile: Across early trials, AOD‑9604 did not increase IGF‑1 and did not worsen glucose tolerance, contrasting with full‑length hGH.
• Cartilage research: Preclinical intra‑articular models (e.g., rabbits) explored joint effects at 0.25 mg per injection; these data do not establish systemic dosing for humans.
• Technique: Rotate injection sites; inject slowly; use sterile supplies and sharps containers.
• Safety first: Discontinue use and consult a qualified professional if significant adverse reactions occur.

05 · How it works

How This Works

AOD-9604 (human growth hormone fragment 177–191) is a short peptide investigated for its effects on fat metabolism.

In preclinical and early clinical research, it has shown lipolytic and anti‑lipogenic activity without elevating IGF‑1 or impairing glucose tolerance.

This page provides an educational dosing and reconstitution framework commonly used for daily subcutaneous administration.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• AOD-9604 observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
• This section is not a claim of therapeutic benefit.

08 · Technique

Injection Technique

09 · Evidence

References